Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
Adult
Aged
Biomarkers
/ blood
Cardiovascular Diseases
/ diagnosis
Cause of Death
Drug Combinations
Dyslipidemias
/ blood
Ezetimibe
/ adverse effects
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ adverse effects
Kidney
/ physiopathology
Lipids
/ blood
Male
Middle Aged
Patient Safety
Randomized Controlled Trials as Topic
Renal Insufficiency, Chronic
/ diagnosis
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
05
12
2019
accepted:
25
03
2020
pubmed:
23
4
2020
medline:
25
5
2021
entrez:
23
4
2020
Statut:
ppublish
Résumé
The efficacy and safety of statin and ezetimibe combination therapy in patients with chronic kidney disease (CKD) remains unclear. To assess the effect of statin and ezetimibe combination therapy on controlling lipid profiles and reducing cardiovascular events in patients with CKD, we conducted a systematic review and meta-analysis. We selected randomized controlled trials comparing this combination therapy with statin monotherapy or placebo in patients with CKD from the PubMed, Embase, and Cochrane Central Register of Controlled Trials databases published before September 1, 2018 on the Internet. Eight articles on seven studies, with a total of 14,016 patients with CKD, were selected from 412 full-text articles. Statin and ezetimibe combination therapy had beneficial effects on serum total cholesterol (weighted mean difference (WMD) -20.31 mg/dL, 95% confidence interval (CI), -26.87 to -13.75 mg/dL, P < 0.001), low-density lipoprotein cholesterol (WMD -17.22 mg/dL, 95% CI, -18.93 to -15.51 mg/dL, P < 0.001), and triglycerides (WMD -15.08 mg/dL, 95% CI, -23.41 to -6.75 mg/dL, P < 0.001) compared with statin monotherapy. Statin and ezetimibe combination therapy significantly reduced all-cause mortality and major adverse cardiovascular events (risk ratio 0.86, 95% CI, 0.77 to 0.97, P = 0.01). The incidence of adverse events was low, with no significant difference between statin and ezetimibe combination therapy and statin monotherapy. In conclusion, the statin and ezetimibe combination therapy significantly improved serum lipid profiles and reduced risks of all-cause deaths and major adverse cardiovascular events compared with the control group in patients with CKD.
Substances chimiques
Biomarkers
0
Drug Combinations
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Lipids
0
Ezetimibe
EOR26LQQ24
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
833-843Informations de copyright
© 2020 The Authors Clinical Pharmacology & Therapeutics © 2020 American Society for Clinical Pharmacology and Therapeutics.
Références
Go, A.S., Chertow, G.M., Fan, D., McCulloch, C.E. & Hsu, C.-y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351, 1296-1305 (2004).
Di Lullo, L., House, A., Gorini, A., Santoboni, A., Russo, D. & Ronco, C. Chronic kidney disease and cardiovascular complications. Heart Fail. Rev. 20, 259-272 (2015).
Jungers, P. et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol. Dial. Transplant. 12, 2597-2602 (1997).
James, M.T., Hemmelgarn, B.R. & Tonelli, M. Early recognition and prevention of chronic kidney disease. Lancet 375, 1296-1309 (2010).
Pinkau, T., Hilgers, K.F., Veelken, R. & Mann, J.F.E. How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease? J. Am. Soc. Nephrol. 15, 517-523 (2004).
Hyre, A.D., Fox, C.S., Astor, B.C., Cohen, A.J. & Muntner, P. The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment. Am. J. Kidney Dis. 49, 37-45 (2007).
Hager, M.R., Narla, A.D. & Tannock, L.R. Dyslipidemia in patients with chronic kidney disease. Rev. Endocr. Metab. Disord. 18, 29-40 (2017).
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002).
Pellicori, P., Costanzo, P., Joseph, A.C., Hoye, A., Atkin, S.L. & Cleland, J.G.F. Medical management of stable coronary atherosclerosis. Curr. Atheroscler. Rep. 15, 313 (2013).
Major, R.W., Cheung, C.K., Gray, L.J. & Brunskill, N.J. Statins and cardiovascular primary prevention in CKD: a meta-analysis. Clin. J. Am. Soc. Nephrol. 10, 732-739 (2015).
Palmer, S.C., Craig, J.C., Navaneethan, S.D., Tonelli, M., Pellegrini, F. & Strippoli, G.F.M. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann. Intern. Med. 157, 263-275 (2012).
Upadhyay, A., Earley, A., Lamont, J.L., Haynes, S., Wanner, C. & Balk, E.M. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann. Intern. Med. 157, 251-262 (2012).
Tonelli, M. & Wanner, C. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann. Intern. Med. 160, 182 (2014).
Yan, Y.-L. et al. High-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis. BMJ. Open 5, e006886 (2015).
Pedersen, T.R. et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294, 2437-2445 (2005).
Mikhailidis, D.P. et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr. Med. Res. Opin. 21, 959-969 (2005).
Daskalopoulou, S.S. & Mikhailidis, D.P. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Curr. Med. Res. Opin. 22, 511-528 (2006).
Davidson, M.H. et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. 40, 2125-2134 (2002).
Ballantyne, C.M., Blazing, M.A., King, T.R., Brady, W.E. & Palmisano, J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am. J. Cardiol. 93, 1487-1494 (2004).
Shamseer, L. et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 350, g7647 (2015).
Levin, A. & Stevens, P.E. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 85, 49-61 (2014).
Guyatt, G. et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J. Clin. Epidemiol. 64, 383-394 (2011).
Landray, M. et al. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am. J. Kidney Dis. 47, 385-395 (2006).
Nakamura, T. et al. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacol. Res. 61, 58-61 (2010).
Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am. Heart J. 160, 785-794.e10 (2010).
Baigent, C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377, 2181-2192 (2011).
Suzuki, H., Watanabe, Y., Kumagai, H. & Shuto, H. Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Ther. Adv. Cardiovasc. Dis. 7, 306-315 (2013).
Hagiwara, N. et al. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur. Heart. J. 38, 2264-2276 (2017).
Stanifer, J.W. et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. J. Am. Soc. Nephrol. 28, 3034-3043 (2017).
Fujisue, K. et al. Impact of statin-ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease - Sub-analysis of PRECISE-IVUS trial. Int. J. Cardiol. 268, 23-26 (2018).
Baigent, C. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670-1681 (2010).
Baigent, C. et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278 (2005).
Bin Abdulhak, A.A. & Robinson, J.G. Optimizing statins and ezetimibe in guideline-focused management. Cardiol. Clin. 36, 221-223 (2018).
Japaridze, L. & Sadunishvili, M. The short-term effect of atorvastatin plus ezetimibe therapy versus atorvastatin monotherapy on clinical outcome in acute coronary syndrome patients by gender. Kardiol. Pol. 75, 770-778 (2017).
Lloyd-Jones, D.M. et al. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J. Am. Coll. Cardiol. 70, 1785-1822 (2017).
Li, Y.-H. et al. 2017 Taiwan lipid guidelines for high risk patients. J. Formos. Med. Assoc. 116, 217-248 (2017).
Thompson, P.D., Clarkson, P. & Karas, R.H. Statin-associated myopathy. JAMA 289, 1681-1690 (2003).
Bowman, L., Armitage, J., Bulbulia, R., Parish, S. & Collins, R. Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors. Am. Heart J. 154, 815-823.e6 (2007).
Link, E. et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med. 359, 789-799 (2008).
García, M.J., Reinoso, R.F., Sánchez Navarro, A. & Prous, J.R. Clinical pharmacokinetics of statins. Methods Find. Exp. Clin. Pharmacol. 25, 457-481 (2003).